How to access Tecfidera from Saudi Arabia, the named-patient import pathway, 2026
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-13.
A Saudi patient with relapsing forms of multiple sclerosis (clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease) may receive a prescription for Tecfidera (dimethyl fumarate) from their treating neurologist with MS expertise. Tecfidera is FDA-approved in the United States and manufactured by Biogen. It is an oral disease-modifying therapy for multiple sclerosis administered by oral capsule. Local availability of Tecfidera in Saudi Arabia can be inconsistent: the drug may not be on every specialty pharmacy's standing formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through SFDA remains a legitimate route for the patient whose physician has already prescribed the drug.
This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.
Ask about Tecfidera in Saudi Arabia
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Tecfidera is an oral disease-modifying therapy for multiple sclerosis. Mechanism: a fumaric acid ester whose active metabolite monomethyl fumarate activates the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway with anti-inflammatory and cytoprotective effects. Dosing: 120 mg twice daily for the first 7 days, then 240 mg twice daily, per FDA labeling. Baseline workup per FDA labeling includes complete blood count with lymphocyte count, liver function tests, and renal function. Other important warnings include anaphylaxis and angioedema, progressive multifocal leukoencephalopathy in patients with prolonged lymphopenia, herpes zoster and other serious opportunistic infections, lymphopenia, liver injury, and flushing. Your neurologist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Tecfidera legally importable into Saudi Arabia?
Yes, through the Saudi Food and Drug Authority (SFDA) named-patient and personal-use import framework, coordinated with the treating facility's pharmacy. Saudi Arabia has an established pathway for specialty medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.
The SFDA named-patient route allows a Saudi-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. Applications are typically filed through the dispensing institution's import pharmacy on the physician's behalf, with approval issued on a per-patient, per-cycle quantity basis.
How the pathway works, step by step
- Consultation with your treating neurologist. The prescribing decision is clinical. Your neurologist documents the indication, prior therapies where relevant, and rationale for Tecfidera.
- Baseline screening. Complete blood count with lymphocyte count, liver function tests, and renal function are confirmed and documented.
- SFDA named-patient application. Your neurologist or the facility's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure product from Biogen's authorised distribution under DSCSA chain-of-custody.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your neurologist initiates therapy.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming diagnosis, prior therapies where relevant, and Tecfidera as the indicated next step
- Verification of their Saudi medical licence
- A patient identifier, anonymised reference where privacy is preferred
- Documented pre-treatment screening consistent with FDA labeling (see above)
- The planned dosing regimen (120 mg twice daily for the first 7 days, then 240 mg twice daily, per FDA labeling)
- A monitoring plan covering lymphocyte monitoring plan, LFT baseline, and PML risk note
Reserve Meds provides a physician documentation kit tailored for oral MS therapy therapies, including the templates SFDA reviewers commonly request.
Typical costs and indicative timing
Reserve Meds gives you a transparent, itemised custom quote at intake. Medicine price: quote on request. You get a written quote for your case before you commit. International logistics, SFDA documentation handling, and coordination add incremental cost. The delivered quote we issue at intake shows each line separately.
We give you a written timeline estimate for your case before you commit. Refills ship on a rolling cadence aligned to the dosing schedule.
Where Reserve Meds fits in
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Tecfidera specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
- Documentation. Regulatory package tailored for your physician and for SFDA review, including oral MS therapy class templates.
- Logistics. Internationally tracked shipment to your named dispensing facility with tamper-evident packaging.
- Dedicated case lead. A named point of contact for your family and your physician across the full case arc.
We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating neurologist, and dispensing sits with the licensed Saudi pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across oncology, rare disease, and immunology at Saudi tertiary centers.
Will my private health insurance cover this? Cash-pay is the default posture. Cash-pay is the default posture in Saudi Arabia; some employer plans cover specialty imports case-by-case. We supply documentation for your submission but do not process insurance claims.
What if my physician has not filed a named-patient request before? Named-patient import is an institutional process most major Saudi tertiary centers (King Faisal Specialist Hospital and Research Centre (KFSHRC) Riyadh, National Guard Health Affairs (NGHA), King Fahad Medical City (KFMC), King Abdulaziz Medical City (KAMC), and King Faisal Specialist Hospital Jeddah) have encountered. Our documentation kit is written for first-time applicants and tracks what SFDA reviewers commonly ask for.
Next step
For Tecfidera coordination in Saudi Arabia, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Composite case examples. This content is for general information and does not constitute medical advice.
Frequently asked questions
How can I get Tecfidera in Saudi Arabia if it is not approved or available there?
Reserve Meds coordinates US-sourced Tecfidera for patients in Saudi Arabia through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Saudi Arabia and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Tecfidera in Saudi Arabia through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Tecfidera. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in Saudi Arabia, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Tecfidera in Saudi Arabia through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Tecfidera to a patient in Saudi Arabia?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Tecfidera to your treating physician or hospital pharmacy in Saudi Arabia, with appropriate handling for the product.
How long does it take, and what does Tecfidera in Saudi Arabia cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Tecfidera in Saudi Arabia?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.